Related Experiment Video

Updated: Oct 1, 2025

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

35.5K

A Glimpse Into the Future of Transcatheter Interventional Heart Failure Therapies

Roberto C Cerrud-Rodriguez1, Daniel Burkhoff2, Azeem Latib1

  • 1Montefiore Einstein Center for Heart and Vascular Care, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York, USA.

JACC. Basic to Translational Science
|March 8, 2022
PubMed

Insights

Chronic heart failure (CHF) remains a major health challenge. This paper reviews emerging catheter-based interventions aimed at improving outcomes for millions affected by this condition.

Area of Science:

  • Cardiology
  • Medical Devices
  • Interventional Cardiology

Background:

  • Chronic heart failure (CHF) affects millions globally, posing a significant healthcare burden.
  • Despite therapeutic advances, morbidity and mortality rates in CHF remain high.
  • Current treatments have limitations, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To provide a technical overview of innovative catheter-based interventional therapies for chronic heart failure.
  • To highlight therapies currently under clinical investigation for CHF management.

Main Methods:

  • Review of current clinical investigations and technical aspects of catheter-based interventions.
  • Focus on therapies targeting diverse physiological and anatomical aspects of heart failure.

Main Results:

  • Identification of multiple catheter-based interventional therapies in various stages of clinical development.
  • Overview of the technical principles and targets of these novel interventions.

Conclusions:

  • Catheter-based interventions represent a promising frontier in managing chronic heart failure.
  • Ongoing research and clinical trials are crucial for advancing CHF treatment paradigms.

Keywords:
CI, confidence intervalCOVID-19, coronavirus disease 2019CS, coronary sinusCVP, central venous pressureHF, heart failureHFpEF, heart failure with preserved ejection fractionHFrEF, heart failure with reduced ejection fractionHR, hazard ratioLA, left atrium/atrialLAP, left atrial pressureLV, left ventricularLVEDV, left ventricular end-diastolic volumeLVEF, left ventricular ejection fractionLVESV, left ventricular end-systolic volumeLVESVi, left ventricular end-systolic volume indexNYHA, New York Heart AssociationPCWP, pulmonary capillary wedge pressureRA, right atrium/atrialRAP, right atrial pressureSVC, superior vena cavacatheter-based therapiesheart failureinterventional heart failure

More Related Videos

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft08:30

A Porcine Heterotopic Heart Transplantation Protocol for Delivery of Therapeutics to a Cardiac Allograft

Published on: February 14, 2022

2.8K
Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

9.5K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
47
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
37
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
55
Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
58
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
547
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
47